UNASSIGNED: Predicting the responses of @entity1 with @entity309 ( @entity309 ) to tocilizumab is difficult, because inflammatory markers such as C-reactive protein rapidly normalize regardless of clinical efficacy. We aimed to identify factors that could predict response to tocilizumab. Sixty-five @entity1 completed 52  weeks of tocilizumab therapy. Serum fibrinogen, D-dimer and interleukin (IL)-1b levels were measured at baseline and after 4  weeks of therapy. Clinical responses to tocilizumab were assessed using disease activity score 28-erythrocyte sedimentation rate and the clinical disease activity index at baseline and after 52  weeks of therapy (UMIN Clinical Trials Registry No. UMIN000002246). Mean age was 60.5  years (range 22-85  years). Mean disease duration was 11.2  years (range 0-45  years). All @entity1 had moderate-to-severe disease activity and were resistant to disease-modifying anti-rheumatic drugs and/or other biologics. Baseline @entity1356 levels were significantly lower in responders than in non-responders (p  =  0.045), but multiple logistic regression analysis found no significant difference (adjusted odds ratio 2.74; 95  % confidence interval 0.84-8.95; p  =  0.096). Low D-dimer and @entity1356 levels at 4  weeks predicted greater decrease in disease activity after 52  weeks of treatment (p  =  0.005 and p  <  0.001, respectively). Effects of tocilizumab at 52  weeks could be predicted from D-dimer and @entity1356 levels after 4  weeks of tocilizumab treatment. These markers might be more useful than current inflammatory markers for early-stage prediction of response to tocilizumab in @entity309 .

Levels of @entity1356 can predict response to tocilizumab therapy in XXXX : the PETITE (predictors of effectiveness of tocilizumab therapy) study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA'] @entity1356 :: ('3553', 'Gene') :: ['IL-1b']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
